Rigel Pharma (RIGL) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.86 -0.04%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported Q1 EPS of ($0.40), $0.04 worse than the analyst estimate of ($0.36).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel to present pralsetinib cancer data at ESMO Congress 2026
- Consumer Portfolio Services (CPSS) Reports Q3 EPS of $0.30
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
